U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17PRNewsWire • 08/19/22
Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth BillionsInvestors Business Daily • 08/19/22
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17PRNewsWire • 08/18/22
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for AdultsPRNewsWire • 08/17/22
Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and OlderPRNewsWire • 08/15/22
Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17PRNewsWire • 08/12/22
Novavax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine ForumPRNewsWire • 08/11/22